Stock fact sheet · data as of
Pharma-Bio Serv, Inc. (PBSV): fair value, margin of safety and Wheel Score
Industrials · Specialty Business Services · Puerto Rico · Speculative / Distressed
Is PBSV undervalued?
At 0.4200 (close of 16 Oct 2026), PBSV trades 33% below the GLS average fair value of 0.6234. That average comes from 2 models run on the latest filings, and 1 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Pharma-Bio Serv, Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
The average is built from just 2 models (DCF, DDM) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files PBSV under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for PBSV
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 0.1433 | -66% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | 1.10 | +163% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 0.5086 | +21% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Pharma-Bio Serv, Inc. scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 2.6/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -0.8%, ROE -0.8%, ROA -0.7% - with debt at 0.00 times equity and negative free cash flow.
The dividend yield is high at 17.86% (payout ratio -25%). A yield this size is often the market's way of pricing a risk to the payout, so the health score and cash flow matter more than usual.
Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | -0.8% |
|---|---|---|---|
| GLS Moat | 2.6 / 10 | ROE | -0.8% |
| Debt / equity | 0.00 | ROA | -0.7% |
| Free-cash-flow yield | -3166.0% | Payout ratio | -25% |
| Institutions | 5 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 39: No options
No options are listed on Pharma-Bio Serv, Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 1k shares a day on a market cap of $10M, with a beta of 0.73 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 33% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 4 / 15 | moat 2.6/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 1k shares/day, $10M cap, beta 0.73 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for PBSV in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Specialty Business Services
The 12 companies below are the closest to Pharma-Bio Serv, Inc. by market cap within the Specialty Business Services industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| EVTK Eventiko Inc. | 2.40 | - | - | 21No options | $10M |
| BBOE Black Box Entertainment Ltd. | 0.5800 | - | - | 20No options | $8M |
| AXNX Axonex AI Group Limited | 0.5128 | - | - | 21No options | $7M |
| THH TryHard Holdings Limited | 1.29 | 20.38 | +94% | 39No options | $6M |
| LICN Lichen International Limited | 0.8900 | 10.42 | +91% | 38No options | $14M |
| MMTRS Mills Music Trust | 22.15 | 45.01 | +51% | 39No options | $6M |
| LMTI Laser Master International, Inc. | 0.5000 | 1.21 | +59% | 39No options | $5M |
| ELVG Elvictor Group, Inc. | 6.30 | 2.60 | -143% | 20No options | $5M |
| CRE Cre8 Enterprise Limited Class A Ordinary Shares | 2.60 | 0.2600 | -900% | 6No options | $5M |
| NSYC National Stock Yards Co. | 412.00 | 133.86 | -208% | 26No options | $18M |
| PMEC Primech Holdings Ltd. Ordinary Shares | 0.5400 | - | - | 27No options | $21M |
| CAHO Caro Holdings Inc. | 0.3700 | - | - | 30No options | $22M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about PBSV
Is PBSV undervalued right now?
By the GLS models, yes: at 0.4200 the stock is 33% below the average fair value of 0.6234 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of PBSV and what does it mean?
PBSV has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for PBSV?
0.6234 per share as of 16 Oct 2026 - the simple average of the 2 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Pharma-Bio Serv, Inc. report earnings next?
No upcoming earnings date is recorded for PBSV in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does PBSV have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on PBSV, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.